McKesson Corporation
Explore McKesson
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
3 leaders · Full leadership timeline
McKesson is best understood as healthcare infrastructure. It moves medicines through a regulated network and supports providers and manufacturers with specialty distribution, oncology services, patient-access programs, technology, and medical supplies. The strategic shift is toward higher-growth oncology, multispecialty, and biopharma services while simplifying the portfolio through the European exit and planned Medical-Surgical separation.
McKesson makes money primarily by purchasing and distributing pharmaceuticals and medical products to pharmacies, hospitals, health systems, and other providers. Distribution is a high-volume, thin-margin business, so purchasing terms, logistics efficiency, order accuracy, customer contracts, and working-capital management drive results. The company also earns service revenue through oncology and multispecialty provider platforms, biopharma services, prescription access and affordability tools, third-party logistics, and medical-surgical distribution.
Chief Executive Officer
Tyler led the organization through the transformative $13.8 billion acquisition of Change Healthcare and the subsequent $13.8 billion opioid litigation settlement, fundamentally transforming the portfolio and positioning the organization for long-term growth in healthcare technology and specialty patient services.
Executive Vice President and Chief Legal Officer
Lerman has maintained the company's fortress balance sheet and disciplined capital allocation strategy, supporting a $1.0 billion R&D budget while simultaneously funding a continuous share repurchase program in FY2024, demonstrating exceptional financial discipline in a flat-to-declining revenue environment.
Executive Vice President and Chief Financial Officer
Ward has been instrumental in driving the strategic pivot toward precision medicine, utilizing the company's advanced data analytics and real-world evidence generation to accelerate clinical trial design and identify novel drug targets in healthcare technology and specialty patient services.
McKesson must manage customer concentration, policy changes affecting drug pricing and 340B arrangements, opioid-related claims, cybersecurity, acquisition integration, and the planned separation of Medical-Surgical Solutions while maintaining high service levels across a low-margin network.